This study is testing an oral drug called CC-486 for adults with a rare blood cancer called T-cell large granular lymphocytic leukemia (T-LGLL) that has come back or hasn't responded to previous treatment. The first part of the trial aims to find the safest and most effective dos…
Phase: PHASE1, PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC